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The emergence of multidrug-resistant bacteria presents a severe threat to public health 
and causes extensive losses in livestock husbandry and aquaculture. Effective strate-
gies to control such infections are in high demand. Enhancing host immunity is an ideal 
strategy with fewer side effects than antibiotics. To explore metabolite candidates, we 
applied a metabolomics approach to investigate the metabolic profiles of mice after 
Klebsiella pneumoniae infection. Compared with the mice that died from K. pneumoniae 
infection, mice that survived the infection displayed elevated levels of l-valine. Our anal-
ysis showed that l-valine increased macrophage phagocytosis, thereby reducing the 
load of pathogens; this effect was not only limited to K. pneumoniae but also included 
Escherichia coli clinical isolates in infected tissues. Two mechanisms are involved in 
this process: l-valine activating the PI3K/Akt1 pathway and promoting NO production 
through the inhibition of arginase activity. The NO precursor l-arginine is necessary for 
l-valine-stimulated macrophage phagocytosis. The valine-arginine combination therapy 
effectively killed K. pneumoniae and exerted similar effects in other Gram-negative 
(E. coli and Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus) 
bacteria. Our study extends the role of metabolism in innate immunity and develops the 
possibility of employing the metabolic modulator-mediated innate immunity as a therapy 
for bacterial infections.
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inTrODUcTiOn
Multidrug-resistant bacterial pathogens, which are unresponsive to antibiotics, pose a substantial 
challenge to human health and animal husbandry. Currently, Gram-negative bacteria with extended-
spectrum beta-lactamases (ESBLs), methicillin-resistant Staphylococcus aureus (MRSA), and 
Mycobacterium tuberculosis are the top three harmful pathogens around the world that can hardly 
be eliminated due to multidrug resistance (1, 2). Among these Gram-negative bacteria with ESBLs, 
Klebsiella pneumoniae is a typical pathogen with high emergence that frequently promote empirical 
therapy failures (3, 4). Therefore, new approaches to treat such infections in the clinic are urgently 
needed. One possible approach would be to enhance the innate immune response of the infected 
host, which would restore the defense ability to kill the bacterial pathogen in a relatively risk-free 
manner (5).
2Chen et al. Valine Promotes Phagocytosis to Kill Bacteria
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 207
Several lines of evidence have demonstrated that bacterial 
infections cause host metabolic changes, including central carbon 
metabolism, amino acid metabolism, and fatty acid metabolism 
(6–10). Pathogens also shift their metabolic programs to adapt 
to their new environment. More importantly, it has been dem-
onstrated that several metabolites can be immunoregulators that 
modulate the function of immune cells (11–23). Examples of such 
metabolites include l-valine, which regulates the maturation and 
function of monocyte-derived dendritic cells (DCs) through a 
nutrient-sensitive signaling pathway (16). These results indicate 
that modulation of host innate immunity by metabolites may be 
a new valuable solution against bacterial pathogens.
Metabolomics is a powerful tool for studying metabolic 
processes, identifying crucial biomarkers responsible for 
metabolic characteristics, and revealing metabolic mechanisms. 
Furthermore, crucial biomarkers can be used to reprogram a 
metabolome, leading to a specific metabolome to cope with 
changes in internal and external environments (23). Using this 
approach, we have identified crucial biomarkers that contribute 
to metabolic mechanisms in bacteria and hosts in response to 
antibiotics and pathogen invasion. The use of these key biomark-
ers reprograms the bacterial and host metabolomes to eliminate 
bacterial resistance to antibiotics and enhances host immunity 
against bacterial infections, respectively (24–32).
Here, we report the use of gas chromatography–mass spec-
trometry (GC-MS) combined with multivariate statistical tools to 
characterize the blood metabolome from BALB/c mice infected 
by sublethal doses of K. pneumoniae. Furthermore, we identified 
a potential immunomodulatory metabolite, l-valine, which 
is capable of enhancing host immunity against K. pneumoniae 
infection. We were specifically interested in understanding 
the metabolic mechanism by which this potential compound 
modulates the survival-related metabolome to enhance cell anti-
infective abilities. The results are reported as follows.
MaTerials anD MeThODs
ethics statement
All work was conducted in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals 
of the National Institutes of Health. The protocol was approved by 
the Institutional Animal Care and Use Committee of Sun Yat-sen 
University (Animal Welfare Assurance Number: I6).
chemicals
Fluorescein isothiocyanate (FITC, F7250), l-valine (V0513), 
l-arginine (A8094), lipopolysaccharide (LPS) (LPS, L4524), and 
S-(2-boronoethyl)-l-cysteine (SML184, arginase inhibitor) were 
purchased from Sigma-Aldrich. LY294002 was purchased from 
KeyGen Biotech, China. Two antibodies, phospho-Akt1-S473 
(AP0140) and β-actin (AC004), were from Abclonal, USA. 
Four nitric oxide (NO) inhibitors, Carboxy-PTIO (PTIO), 
l-NMMA, SMT, and l-NAME, were purchased from Beyotime 
Biotechnology, China. The urea assay kit and Nitric Oxide Assay 
Kit were purchased from BioVision (Mountain View, CA, USA) 
and Beyotime (Beijing, China), respectively. LY294002 was 
dissolved in DMSO. Meanwhile, the equal volume of DMSO 
was also added in the other groups of this experiment as solvent 
control to exclude the effects of DMSO on phagocytosis.
Bacterial strains, culture conditions, and 
experimental animals
All bacterial species in this study were obtained from the col-
lection maintained at our laboratory. The bacterial strains used 
in the present study consisted of the following clinical isolates: 
K. pneumoniae (No. 0367 and No. 1924), Escherichia coli, MRSA, 
and Pseudomonas aeruginosa. The E. coli MCC-5 and HCC-13 
were isolated from chickens, and the other bacteria were isolated 
from humans. The bacterial strains were cultured from frozen 
stocks in LB medium in a shaker bath at 37°C. Bacterial cells 
from overnight cultures were diluted 1:100 into 100 mL of LB 
medium. The cultures were harvested at an absorbance of 1.0 
(OD600) by centrifugation at 7,000  rpm for 15  min at 4°C. 
The cells were washed in 40 mL of sterile saline (0.85% NaCl) 
and then resuspended in 0.85% NaCl. Male mice (BALB/c, 
pathogen-free), weighing 24 ±  2  g from the same litters and 
obtained from the Animal Center of Sun Yat-sen University, 
were reared in cages fed with sterile water and dry pellet diets. 
Between 50 and 100 μL blood was obtained from the orbital vein 
of each mouse as the non-infection group. Then, each mouse 
was intraperitoneally or intravenously infected by inoculation 
with the indicated colony-forming units (CFUs) of bacteria. 
Equal amounts of blood were collected from each mouse in 
the experimental group at 6  h post-infection using the same 
approach as for before infection. The experimental group was 
further divided into the dead and survival groups at 15  days 
depending upon whether the mice either succumbed to the 
infection or survived after infection.
Metabolite extraction in Mouse Plasma
Total metabolites extracted from plasma were performed as 
described previously (27). Briefly, 50 μL plasma was quenched 
by using 50 μL cold methanol and collected by centrifugation at 
8,000 rpm for 3 min. This step was repeated two times. The two 
supernatants were mixed, and aliquot of sample was transferred 
to a GC sampling vial containing 5 μL 0.1 mg mL−1 ribitol (Sigma) 
as an analytical internal standard and then dried in a vacuum 
centrifuge concentrator before the subsequent derivatization. 
Two technical replicates were prepared for each sample.
Derivatization and gc-Ms analysis
Samples must be derived before GC-MS analysis. Therefore, 
80 μL of methoxamine/pyridine hydrochloride (20 mg mL−1) was 
added to dried samples to induce oximation for 1.5 h at 37°C, 
and then 80  μL of the derivatization reagent MSTFA (Sigma) 
was mixed and reacted with the sample for 0.5 h at 37°C. A 1 μL 
aliquot of the derivative of the supernatant was added to a tube 
and analyzed using GC-MS (Trace DSQ II, Thermo Scientific). 
The separation conditions of GC-MS consisted of an initial 
temperature of 70°C (5 min) with a uniform increase to 270°C 
at a speed of 2°C min−1 (5 min); 0.5 μL sample volume, splitless 
injection; injection temperature, 270°C; interface temperature, 
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270°C; ion source (EI) temperature, 30°C; ionization voltage, 
70 eV; quadrupole temperature, 150°C; carrier gas, highly pure 
helium; velocity, 1.0 mL min−1; and full scan way, 60–600 m/z.
In data processing, spectral deconvolution and calibration 
were performed using AMDIS and internal standards. A retention 
time (RT) correction was performed for all the samples, and then 
the RT was used as reference against which the remaining spectra 
were queried and a file containing the abundance information for 
each metabolite in all the samples was assembled. Metabolites 
from the GC-MS spectra were identified by searching in National 
Institute of Standards and Technology (NIST) library used the 
NIST MS search 2.0. The resulting data matrix was normalized 
using the concentrations of added internal standards that were 
subsequently removed so that the data could be used for mod-
eling consisted of extracted compound. The resulting normalized 
peak intensities formed a single matrix with Rt-m/z pairs for 
each file in the dataset. To reduce between-sample variation, we 
centered the imputed metabolic measures for each tissue sample 
on its median value and scaled it by its interquartile range (28). 
The z-score analysis scaled metabolites according to a reference 
distribution. The control samples were designated as the refer-
ence distribution. Thus, the mean and SD of the control samples 
were determined for each metabolite. Then, each sample was 
centered by the control mean and scaled by the control SD, per 
molecule. In this way, we can know how the metabolite expres-
sions deviated from the control state. In addition, independent 
component analysis (ICA) was selected as the pattern recognition 
method (25).
Western Blotting
RAW264.7 cells were lysed in 4 ×  loading buffer [250 mM Tris 
pH 6.8, 8% (w/v) SDS, 40% glycerol, 20% β-mercaptoethanol, 
and 0.01% bromophenol blue] and boiled for 10  min. After 
centrifugation, 50 μg of total protein extracts was separated by 
12% SDS-PAGE, which was then transferred to nitrocellulose 
membranes for Western blotting. After blocking with 3% bovine 
serum albumin dissolved in Tris-buffered saline (TBS) containing 
0.05% Tween-20 for 1 h at room temperature, the membranes were 
incubated with anti-phospho-Akt1-S473 or anti-β-actin primary 
antibodies at appropriate dilutions, followed by goat anti-rabbit 
or anti-mouse secondary antibodies conjugated with horseradish 
peroxidase, respectively. Positive band intensities were detected 
using a gel documentation system (LAS-3000 Fujifilm Medical 
Systems, Stamford, CT, USA).
Therapeutic effect of l-Valine or/and 
l-arginine on Bacterial eradication
Mice were acclimatized for 1 week and then randomly divided 
into groups for the investigation on the therapeutic effects of 
l-valine, l-arginine, or both. Mice were intraperitoneally chal-
lenged by bacterial pathogens (K. pneumoniae, MRSA, P. aerugi-
nosa, or E. coli strains isolated from humans and chicken). Prior 
to killing by decapitation and extracting spleen, liver, and kidney 
tissues at 24  h, l-valine (0.5  g  kg−1), l-arginine (0.25  g  kg−1), 
l-valine (0.5  g  kg−1) plus l-arginine (0.25  g  kg−1) or an equal 
volume of sterile saline were intravenously administered to the 
bacteria-challenged mice at 1, 4, 7, 10, and 20 h through the tail 
vein. Replacement of l-valine or l-valine/l-arginine with d-valine 
or d-valine/l-arginine, respectively, was used as a control. The tis-
sues were ground using sterile saline in gnotobasis. Plate counting 
was utilized to investigate bacterial eradication in the tissues. The 
homogenates were diluted in appropriate multiples and aliquots 
of the diluted homogenates were sampled in LB solid medium. 
Bacteria were counted when single colonies appeared in the 
medium after growing at 37°C. Differences between the groups 
were tested for significance at two significance levels (0.05 and 
0.01) using the Statistical Package for the Social Sciences statisti-
cal software.
cell culture and Quantitative 
Phagocytosis assay
The murine macrophage cell line RAW264.7 was cultured at 37°C 
in a 5% CO2 incubator in DMEM (HyClone) supplemented with 
10% (V/V) cosmic calf serum (HyClone), 100 U mL−1 penicillin 
G and 100  U/mL streptomycin. Macrophage phagocytosis was 
examined as described previously (26). Briefly, RAW264.7 cells 
were harvested using CaCl2- and MgCl2-free PBS containing 
5 mM EDTA and plated at 5 × 106 macrophages/well in 6-well 
plates. For experiments with administration of the indicated 
concentrations of l-valine, LPS, l-arginine, arginase inhibitor, 
or NO inhibitor, the cells were deprived of serum overnight and 
then incubated alone or additively with the abovementioned 
molecules for the indicated times in serum-starved media, 
including DMEM, l-valine-free medium (DMEM without 
l-valine), l-arginine-free medium (DMEM without l-arginine), 
and l-valine and l-arginine-free medium (DMEM without 
l-valine and l-arginine). After pretreating for 6  h, E. coli-GFP 
or FITC-conjugated K. pneumoniae cells were centrifuged onto 
macrophages at a multiplicity of infection of 100 in the indicated 
medium without serum or antibiotics. Then, the plates were 
placed either in 37°C or 4°C for the indicated times. After infec-
tion, the macrophages were vigorously washed with cold PBS to 
stop additional bacterial uptake or to destroy the bacteria in the 
phagosomes. Cells were washed at least four times in cold PBS 
and then fixed in 4% paraformaldehyde before being harvested 
in cold PBS containing 5  mM EDTA and subjected to FACS® 
analysis.
Ultra Performance liquid chromatography 
(UPlc)-Ms analysis for extra- and 
intracellular l-Valine and l-arginine
l-valine or l-valine plus NO inhibitors were added into l-valine-
free DMEM and then incubated with RAW264.7 cells. After 3 h 
incubation, 100 μL aliquots of medium were mixed with 400 μL 
of acetonitrile. The mixture was mixed by vortex for 2 min, fol-
lowed by centrifugation at 14,000  rpm for 10  min at 4°C. The 
cells were lysed by sonication in 400 μL extraction solution (50% 
acetonitrile and double-distilled water). After centrifugation, the 
supernatants from medium or cell samples were transferred and 
diluted at a ratio of 1:1 with acetonitrile, which was used for sub-
sequent analysis of UPLC/MS-MS. Approximately 90 μL ACN 
were added to 30 μl mice serum sample. The mixture was mixed 
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by vortex for 1 min, followed by centrifugation at 12,000 rpm for 
10 min at 4°C. Murine tissues were homogenized in a laboratory 
homogenizer for 3 min. Then, 1 mL ACN was added to the sample. 
The samples were disrupted by sonication for 2 min, followed by 
centrifugation at 12,000 rpm for 10 min at 4°C. The supernatant 
was collected and analyzed by UPLC-MS/MS.
Ultra performance liquid chromatography analysis was per-
formed on a Waters ACQUITY UPLC system equipped with an 
Acquity BEH C18 column (50 mm × 2.1 mm i.d., 1.7 μm; Waters 
Corp.). The sample was injected during the loading step by the 
loading pump and auto-sampler onto the column. Separation was 
using linear gradient elution with mobile phase A (acetonitrile) 
and B (10 mM ammonium acetate with 0.1% formic acid in ultra-
pure water) at a flow rate of 0.25 mL min−1. The gradient elution 
was as follows: 0–0.5 min, 95% A; 0.5–2 min, 20% A; 2–2.5 min, 
20% A; 2.5–4 min, 95% A. The injection volume was 10 μl, and 
the column temperature was kept at 35°C. Mass spectrometry 
detection was carried out in QUATTRO PREMIER XE equipped 
with an electrospray ionization source operating in positive ioni-
zation mode (ESI+). The capillary voltage was set to 3,000 V; the 
cone voltage was set to 20 V. The extractor voltage and RF Lens 
were set at 1 and 0.5 V, respectively. The desolvation gas flow was 
set to 650 L h−1 at temperature of 450°C, the cone gas flow rate 
was set at 50 L h−1, and the source temperature was set at 120°C. 
Identification was measured in MRM mode, the precursor ion 
and quantifier ion of l-arginine and l-valine was 175 > 70 and 
118 > 72.
nO, Urea concentration, and arginase 
activity Measurements
Total NO concentration in culture medium and cells was calcu-
lated by measuring the nitrate and nitrite concentrations with a 
Total Nitric Oxide Assay Kit (Beyotime, China) according to the 
manufacturer’s instructions. The optical densities at 540 nm were 
recorded using a Microplate Reader (Thermo MutliscanMK3; 
Thermo Fisher Scientific, Waltham, MA, USA). The concentra-
tion of NO output was calculated from the standard curve. Urea 
production was determined using a Urea Colorimetric Assay Kit 
(BioVision). Five million macrophages were harvested and lysed 
for 30  min in 100 μL of 10  mM Tris–HCl, pH 7.4, containing 
0.4% (w/v) Triton X-100. Then, the cells were centrifuged at 
13,000  rpm for 10  min. The supernatant was collected for the 
Arginase Activity Assay kit (Sigma, MAK112). The quantitative 
data were expressed as the mean ± SD. One-way ANOVA was 
used to determine the statistical significance.
effect of Mouse serum on Killing K. 
pneumoniae in the absence and Presence 
of l-Valine
l-valine (0.5 g kg−1) or equal volumes of sterile saline were intra-
venously administered to the mice through the tail vein. Two 
hours later, serum was collected from these mice. K. pneumoniae 
at an absorbance of 1.0 (OD600) in LB medium were harvested by 
centrifugation at 7,000 rpm for 15 min at 4°C. The cultures were 
washed and then resuspended in 0.85% NaCl. Equal amounts of 
K. pneumoniae (~104 CFU) were added into the serum of both 
groups in a final volume of 150 μL. Samples were incubated at 
37°C for 24 h with slow rotation. K. pneumoniae dilutions were 
plated on LB agar for colony formation.
effect of Valine and arginine on Bacterial 
growth
Klebsiella pneumoniae-0367 and E. coli Y17 were cultured in LB 
medium for 16 h at 37°C. Samples were harvested at 7,000 rpm 
for 5 min, washed three times with 30 mL sterile saline and resus-
pended in sterile saline to 0.6 at OD600. Different concentrations 
of valine or arginine were added to the samples to reach a final 
volume of 5 mL; no metabolite was used a control. Samples were 
incubated at 37°C for 6 h. After incubation, 100 μL aliquot samples 
were removed periodically, serially diluted, and plated on LB agar. 
The plates were incubated at 37°C for 8–10 h. Only those dilutions 
that generated 20–200 clones were counted to calculate the CFUs. 
Percent survival was determined by dividing the CFU obtained 
from a treated sample by the CFU obtained for the control.
resUlTs
Metabolomic Profiling of Plasma from 
surviving and Dead Mice following K. 
pneumoniae infection
Mice infected with LD50 K. pneumoniae (No. 0367) producing 
TEM-type ESBLs (Figure S1 in Supplementary Material) dis-
played two consequences: either succumbing to or surviving the 
infection (Figure 1A). Plasma samples were drawn from the mice 
6 h post-infection; serum drawn before infection served as the 
control group (Figure 1B). Metabolic profiling of the plasma sam-
ples was performed using a GC-MS-based approach followed by 
multivariate analysis to identify crucial biomarkers. The reliability 
of GC-MS was assessed through correlation coefficients with two 
technical repeats (Figure S2A in Supplementary Material). A total 
of 68 metabolites were detected in each sample; internal standard 
and solvent peaks were excluded. The metabolites are displayed 
as a heat map and Z-score plot (Figures S2B,C in Supplementary 
Material). ICA identified two independent components, IC01 
and IC02, whereby IC01 differentiated three groups without any 
significant outliers (Figure S2D in Supplementary Material), 
indicating the reproducibility of the samples.
Pattern recognition identifies l-Valine as 
a Potential anti-infection Metabolite
A two-sided Wilcoxon rank-sum test coupled with a permutation 
test was used to identify crucial biomarkers that differentiated 
these three groups (27). Compared with the control group, 
the abundance of 56 and 50 metabolites were significantly 
altered in the dead and survival groups (p < 0.05), respectively 
(Figures  1C,D), among which 42 metabolites were shared. 
Among the 42 metabolites, 20 metabolites were increased, 20 
metabolites were decreased, and 2 metabolites were increased 
in the survival group but lower in the dead group. In addition 
to the shared metabolites, seven metabolites were increased, and 
seven metabolites were decreased in the dead group, whereas two 
FigUre 1 | continued
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FigUre 1 | continued 
Differential analysis coupled with pathway enrichment analysis identifies l-valine as a potential anti-infective metabolite. (a) Survival percentage for 
mice infected with sublethal doses of Klebsiella pneumoniae. Based on the pretest, the sublethal dose of K. pneumoniae was determined to be 1 × 108 CFU.  
(B) Experimental design for sample acquisition for gas chromatography–mass spectrometry (GC-MS)-based metabolomics. Prior to infection, 100 μL blood was 
drawn from the orbital vein in each of 20 mice as the control group. Eighteen hours later, a half-lethal dose of K. pneumonia was intraperitoneally injected into each 
mouse. Six hours after infection, 100 μL blood was collected. Survival of all the mice was observed for 15 days. (c) Heat map showing the relative abundance of the 
56 and 50 significantly differential metabolites in the dead and survival groups as indicated, respectively. (D) Z-score plots corresponding to the data in panel (c). 
The upper panel is the dead group, and the lower panel is the survival group. (e) Venn diagram showing the overlap of differential metabolites between the dead and 
survival groups. Decreased and increased metabolites are indicated with green and red arrows, respectively. (F) Pathway enrichment of differential metabolites in the 
dead and survival groups. A horizontal histogram was selected to show the impact of the enriched pathway with impact values >0.1. (g,h) Abundance of l-leucine, 
l-valine, and l-threonic acid in the control, dead, and survival groups. Error bars ± SEM, *p < 0.05 and **p < 0.01.
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metabolites were increased and six metabolites were decreased in 
survival group (Figure 1E).
In the pathway analysis, the differential abundance of 50 
metabolites in the survival group and 56 metabolites in the 
dead group enriched for four and three pathways (p < 0.05 and 
impact >  0.1), respectively (Figure  1F). The shared pathways 
were valine, leucine, and isoleucine metabolism, and galactose 
metabolism. All of the detected metabolites from galactose 
metabolism, including d-glucose, mannose, fructose, galactose, 
and myo-inositol, were decreased in both the survival and dead 
groups (Figure S2E in Supplementary Material). Two metabo-
lites, l-valine and l-leucine, were enriched in valine, leucine, and 
isoleucine metabolism. Although the abundance of l-leucine was 
increased in both the survival and dead groups, no significant 
differences were detected between the two groups (Figure 1G). 
By contrast, l-valine and l-threonic acid were differentially 
expressed between the two groups (Figures  1D,H). The abun-
dance of l-valine was higher than l-threonic acid in the survival 
group. Therefore, l-valine could be a prognostic biomarker for K. 
pneumoniae infection and could act as a modulator for protecting 
the host against infection.
exogenous l-Valine Displays an anti-
infective effect on Bacterial infection
The concentrations of l-valine in the control, dead, and survival 
mice were 9, 5, and 17 μM, respectively, as normalized to the inter-
nal standard control ribitol (0.1 mg mL−1, 5 μL). Thus, l-valine 
levels should increase at least two-fold to promote survival during 
bacterial infection. To examine the potential anti-infective role 
of l-valine in vivo, two groups of mice were i.p. injected with K. 
pneumoniae, followed by i.v. injection with l-valine (0.5 g kg−1) 
or sterile saline five times within 20 h. The levels of l-valine, but 
not l-arginine, were significantly elevated in plasma at different 
time points (Figures S3A,B in Supplementary Material). All of 
the mice were sacrificed at 24 h after infection. The liver, spleen, 
and kidney were removed surgically for analysis of bacterial 
load and l-valine. Bacterial counts were significantly lower and 
l-valine was significantly higher in the liver, spleen, and kidney 
of the mice injected with l-valine than those in the saline control 
group (Figure  2A; Figure S3C in Supplementary Material). 
Similar results were obtained when the mice were exposed to a 
clinical strain of antibiotic-resistant E. coli Y17 (Figure 2B). The 
replacement of l-valine with d-valine had a similar bacterial load 
as the saline control (Figures S4A,B in Supplementary Material), 
thus excluding the non-specific effect of l-valine on mice. These 
data strongly suggest that l-valine decreases bacterial load in 
K. pneumonia- and E. coli-infected mice.
To exclude the possibility that l-valine exerts its effects 
through the complement system or immunoglobulins, we 
investigated the effect of l-valine on bacterial growth in the 
presence of freshly drawn murine serum. The growth of bacteria 
was unaffected even in the presence of l-valine (Figure S4C in 
Supplementary Material), implying that l-valine-mediated 
bacterial elimination was unlikely attributed to the comple-
ment system and immunoglobulins. Thus, to further explain 
the anti-infective effects of l-valine on infected mice, we sur-
mised that l-valine might stimulate phagocytosis, which would 
thereby increase the rate at which pathogens were eliminated 
from the host. This hypothesis was tested in vitro by examining 
the cytoplasmic mean fluorescence intensity (MFI) in murine 
macrophages (RAW264.7). l-Valine-pretreated RAW264.7 
cells were incubated with FITC-conjugated K. pneumoniae or 
green fluorescent protein (GFP)-expressing E. coli. l-valine 
markedly stimulated the phagocytosis of fluorescence-tagged 
bacterial pathogens at 0.4–10 mM in a dose-dependent manner 
(Figure 2C). However, phagocytosis was not changed in d-valine 
-pretreated RAW264.7 cells (Figure S4D in Supplementary 
Material). Other amino acids, such as glycine, were unable to 
enhance phagocytosis (Figure S4E in Supplementary Material). 
These results support the immunomodulatory function of 
l-valine in macrophages. Notably, high doses of l-valine 
(20–40 mM) had no significant impacts on normal phagocytosis 
levels, even though high l-valine doses had fewer effects than 
lower l-valine doses (Figure 2C). Additionally, l-valine alone 
did not affect bacterial growth (Figure S4G in Supplementary 
Material). Plate counting revealed that incubation with l-valine 
reduced the bacterial load in extracellular environments 
and enhanced the bacterial load within cells (Figure S4H in 
Supplementary Material).
During infection with Gram-negative bacteria, including 
K. pneumoniae and E. coli, LPS is abundantly produced and 
therefore contributes to immune response. Therefore, the effect 
of l-valine on phagocytosis was examined upon LPS stimulation. 
Macrophages treated with l-valine displayed higher phagocy-
tosis than untreated macrophages, even in the presence of LPS 
(Figure 2D). Additionally, phagocytosis was also further boosted 
by pretreatment with LPS for 1  h as well as when followed by 
FigUre 2 | effect of exogenous l-valine on bacterial load in infected mice and macrophage-mediated phagocytosis. (a,B) l-valine promotes the 
clearance of clinical (a) Klebsiella pneumoniae (No. 0367) and (B) Escherichia coli Y17 in mice (n = 10). (c) Representative flow charts (left) and the mean 
fluorescence intensity (MFI) (MFI, right) of FITC-conjugated K. pneumoniae and GFP-E. coli in l-valine-pretreated RAW264.7 cell at the indicated concentrations at 
3 h. (D) Effect of exogenous l-valine on the phagocytosis of GFP-E. coli in the absence and presence of lipopolysaccharide (LPS) administration. (e) Synergetic 
effects of LPS and l-valine on macrophage phagocytosis. The left histogram indicates the MFI of GFP-E. coli in macrophages treated with LPS for 1 h and 
subsequently treated with LPS plus l-valine for 2 h. The right histogram reveals the MFI of GFP-E. coli in macrophages treated with l-valine for 1 h and subsequently 
treated with LPS plus l-valine for 2 h. Error bars ± SEM, *p < 0.05 and **p < 0.01.
FigUre 3 | activation of Pi3K/akt by exogenous l-valine is essential 
for increased phagocytosis. (a) Phosphorylation of Akt1 at Ser473 was 
examined in RAW264.7 cells treated with l-valine for 3 h. (B) Mean 
fluorescence intensity (MFI) of GFP-E. coli in RAW264.7 cells exposed to 
l-valine in the absence or presence of LY294002 (10 μM), an inhibitor of 
PI3K. Error bars ± SEM, *p < 0.05 and **p < 0.01.
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2 h LPS plus l-valine treatment or by 1 h l-valine followed by 
2 h l-valine plus LPS treatment (Figure 2E). These data support 
that l-valine enhances macrophage-mediated innate immunity 
to Gram-negative pathogens.
l-Valine-induced Pi3K/akt1 activation and 
nO Production contribute to the 
enhanced Phagocytosis
A previous study showed that depletion of extracellular 
l-valine in DCs decreased the mTORC1/S6K-signaling path-
way (16), which is activated by PI3K/Akt (33). Consistently, 
l-valine-treated macrophages displayed increased phospho-
Akt1 (p-Akt1) (Figure 3A). When macrophages were treated 
with the PI3K inhibitor LY294002 (10 μM), the macrophage 
MFI was lower than in untreated cells, regardless of the pres-
ence of LPS (Figure 3B). In particular, upon LPS stimulation, 
LY294002 obviously reduced almost half of the phagocytosis 
enhanced by l-valine (Figure  3B). Thus, l-valine-induced 
activation of PI3K/Akt1 is partly responsible for the improved 
phagocytosis.
It has also been reported that the addition of l-valine led to 
a concentration-dependent decrease in urea and NO produc-
tion in tissues and endothelial cells when arginase is inhibited 
(34, 35). We therefore hypothesized that NO production was 
involved in l-valine-enhanced phagocytosis. First, exogenous 
l-valine increased intracellular levels of l-valine as quantified 
by UPLC-MS (Figure  4A), indicating that l-valine functions 
inside macrophages. Consistent with a previous finding (34), 
exogenous l-valine concentrations ranging from 0.4 to 10 mM 
prompted NO production but reduced urea production extra- 
and intracellular levels in a dose-dependent manner. Higher 
concentrations of l-valine had weaker effects (Figures 4B,C). 
LPS stimulation further enhanced l-valine-induced NO pro-
duction (Figure 4B). Meanwhile, l-valine inhibited RAW264.7 
cell arginase activity (Figure  4D). The inhibition of arginase 
FigUre 4 | exogenous l-valine enhances macrophage phagocytosis by boosting nO production. (a) Detection of extra- and intracellular l-valine in 
l-valine-stimulated macrophages. (B) Effect of exogenous l-valine on NO production by macrophages in the absence or presence of lipopolysaccharide (LPS).  
(c) Effect of l-valine on urea production by macrophages in the absence or presence of LPS. (D) l-valine inhibited arginase activity in RAW264.7 cells. (e) The 
potent and specific arginase inhibitor S-(2-boronoethyl)-l-cysteine suppressed macrophage phagocytosis in a dose-dependent manner. (F) Effect of NO inhibitors 
on l-valine-stimulated phagocytosis by macrophages in the absence or presence of LPS at 3 h. (g) Effect of NO inhibitors on l-valine-stimulated phagocytosis by 
macrophages at the indicated times and in the absence or presence of LPS. Error bars ± SEM, *p < 0.05 and **p < 0.01.
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activity with S-(2-boronoethyl)-l-cysteine, a potent and spe-
cific inhibitor, significantly boosted macrophage phagocytosis 
(Figure  4E). These data provide a strong interrelationship 
between l-valine-induced phagocytosis and NO production. 
To further prove this idea, we investigated the effects of four 
other NO inhibitors, carboxy-PTIO (PTIO, NO scavenger), 
l-NMMA (inhibition of total NO synthase), SMT [inhibition 
of inducible NO synthase (iNOS)], and l-NAME (inhibition of 
endothelial NO synthase), on l-valine-induced phagocytosis. 
As expected, these inhibitors significantly suppressed l-valine-
induced macrophage phagocytosis with or without LPS treat-
ment (Figure  4F), and MFI decreased in a time-dependent 
manner (Figure  4G). Together, these data reveal that PI3K/
Akt1 activation and NO production all contribute to l-valine-
enhanced phagocytosis.
l-arginine is involved in l-Valine-Mediated 
Phagocytosis
Because l-arginine is the exclusive source of NO in cel-
lular metabolism, the role of l-arginine in l-valine-mediated 
phagocytosis was investigated. Removal of l-arginine from the 
culture medium reduced basal phagocytosis levels (Figure 5A). 
l-arginine does not affect bacterial survival (Figure S4D in 
Supplementary Material). However, replacement of l-arginine 
with d-arginine had no effect on macrophage phagocytosis (Figure 
S4G in Supplementary Material), indicating the specific effect of 
l-arginine on phagocytosis. When different concentrations of 
l-arginine or l-valine were added to medium deficient in both 
l-valine and l-arginine, respectively, exogenous l-arginine was 
not effective and even countered phagocytosis (Figures  5B,C). 
However, the addition of 10 mM l-valine increased phagocytosis 
in the absence or presence of LPS (Figures 5B,C). Therefore, we 
believed that the increased phagocytosis that occurred at 10 mM 
in valine-incubated cells was specific and might be caused by 
eNOS, which is constitutively expressed in RAW264.7 mouse 
macrophages (36). We proposed that 10  mM valine was able 
to inhibit arginase activity, thereby elevating NO production 
through eNOS metabolism, which thus enhanced phagocytosis. 
However, the MFI increase was very slight because of the limited 
l-arginine within the cells (Figure 5B). Lower concentrations of 
valine probably did not optimize the inhibition of arginase activity 
FigUre 5 | l-arginine is required for l-valine-mediated phagocytosis. (a) l-Arginine (0.4 mM) is required for basal macrophage phagocytosis. RAW264.7 
cells are cultured in two types of DMEM, l-arginine-free DMEM and DMEM containing 0.4 mM l-arginine. Phagocytosis of GFP-E. coli was quantified by flow 
cytometry [macrophage mean fluorescence intensity (MFI)]. (B) By employing DMEM deficient in both l-valine and l-arginine as the background medium, exogenous 
l-valine only promotes a slight increase in phagocytosis of GFP-E. coli, whereas exogenous l-arginine is not effective and even counters phagocytosis. Different 
concentrations of l-valine or l-arginine are added to DMEM deficient in both l-valine- and l-arginine, and then GFP-E. coli phagocytosis is measured by flow 
cytometry. (c) l-arginine promotes l-valine-mediated phagocytosis in the absence or presence of lipopolysaccharide (LPS). DMEM without both l-valine- and 
l-arginine is used as background medium and 10 mM l-valine, 0.4 mM l-arginine, and 10 mM l-valine plus 0.4 mM l-arginine are added. Phagocytosis of GFP-E. 
coli is investigated in the absence or presence of LPS by flow cytometry. (D) Different combinations of l-valine and l-arginine have varying effects on the 
phagocytosis of GFP-E. coli. The results shown by a red line indicate that macrophage phagocytosis is synergistic with 10 mM l-valine at different l-arginine 
concentrations. The results shown by a green line reveal that macrophage phagocytosis is synergistic with 10 mM l-arginine and different l-valine concentrations. 
The background medium is DMEM without both l-valine and l-arginine. (e) l-arginine levels are measured in l-valine-incubated macrophages in the absence or 
presence of LPS by using ultra performance liquid chromatography (UPLC)-MS. (F) NO inhibitors eliminated the effects of l-valine on l-arginine levels in the absence 
or presence of LPS. The l-arginine levels in the cells and medium are detected by UPLC-MS analysis. Error bars ± SEM, *p < 0.05 and **p < 0.01.
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and higher concentrations, such as 40 mM valine, might promote 
cellular side effects (see details in Section “Discussion”), thereby 
resulting in the decrease in the MFI. Macrophages displayed 
the highest levels of phagocytosis when 10  mM l-valine and 
l-arginine were used (Figure 5D). Regardless of the presence of 
LPS, l-arginine was decreased in l-valine-treated macrophages 
and macrophage-cultured medium (Figure  5E), which could 
be restored by additional treatment with NO inhibitors, except 
for PTIO (Figure 5F). It is possible that PTIO is a specific NO 
scavenger and has limited effects on NO synthase activity, which 
directly metabolizes l-arginine to produce NO, thereby main-
taining or even increasing the consumption rate of l-arginine. 
Together, these data indicate that l-arginine is essential for the 
l-valine-induced phagocytosis and potentially has a synergetic 
effect on bacterial elimination in vivo.
l-Valine and l-arginine synergistically 
Protect Mice against clinically relevant 
Multidrug-resistant Bacteria
Clinically relevant multidrug-resistant bacteria are associated 
with therapy failures and public health crises that are hard to 
be or even no longer controlled by antibiotics, which must be 
addressed with new treatments (37, 38). Therefore, it would be 
clinically helpful if the combined administration of l-valine and 
l-arginine promotes innate immunity-dependent killing of these 
multidrug-resistant bacteria. To test this idea, K. pneumonia-
challenged mice were treated with l-valine, l-arginine, or both 
via intravenous injection. l-valine alone enhanced the elimina-
tion of K. pneumoniae by the host, whereas injection of both 
of l-valine and l-arginine had stronger effects (Figure  6A), 
which was supported by elevated l-valine and l-arginine levels 
in the plasma and kidney (Figures S3A,B,D in Supplementary 
Material). However, neither d-valine nor d-arginine alone 
could eliminate K. pneumoniae and E. coli Y17 (Figures S4A,B 
in Supplementary Material), indicating the specific effects of 
l-valine and l-arginine. Valine–arginine combination therapy 
was also tested in other clinical multidrug-resistant pathogens, 
including Gram-positive and -negative bacteria isolated from 
humans or chickens; this combination also displayed therapeutic 
effects against these pathogens (Figure 6B). These findings indi-
cate that valine–arginine combination therapy could be a useful 
intervention in infectious diseases caused by multidrug-resistant 
bacteria.
FigUre 6 | Therapeutic effects of l-valine and l-arginine synergistic administration on mice infected with clinically relevant multidrug-resistant 
bacteria. (a) Mice administered combined l-valine with l-arginine display stronger elimination of clinical Klebsiella pneumoniae than mice are administered l-valine 
or l-arginine alone (n = 10). (B) Administration of l-valine with l-arginine likely protects mice against other clinical isolates including K. pneumoniae, methicillin-
resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, human-derived Escherichia coli, and chicken-derived E. coli. Error bars ± SEM, *p < 0.05 and 
**p < 0.01.
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DiscUssiOn
Intensive and inappropriate use of antibiotics dramatically leads 
to the development of drug resistance in bacterial pathogens, 
increasing the risk of severe diseases or death after exposure to 
multidrug-resistant bacteria (5, 39). Although antibiotics are still 
the first choice for treating such infections, severe consequences 
would be expected if more multidrug-resistant bacteria were 
generated and spread. A novel strategy for controlling such a 
situation is urgently needed. Our previous studies strongly sug-
gested that the harnessing alanine and glucose, metabolites that 
are suppressed in antibiotic-resistant bacteria, could revert such a 
phenotype (24). The idea of using metabolites to reprogram exist-
ing metabolic pathways to a way that we want has been tested in 
many other species (23). Here, we show that metabolite-mediated 
reprogramming is not limited to bacteria, but is possible in the 
host as well. We identified that l-valine is a key metabolite for 
promoting mouse survival under K. pneumoniae challenge; 
this effect could also be observed with other pathogens such 
as E. coli, P. aeruginosa, or MRSA, implying that l-valine may 
be a metabolite that regulates immune functions. Not surpris-
ingly, we found that l-valine actually increases macrophage 
phagocytosis in an l-arginine-dependent manner. The enhanced 
phagocytosis was attributed to increased PI3K/Akt1 activation 
and NO production (Figure 7). Thus, our study not only proposes 
the use of metabolites in managing bacterial infection but also 
presents a well-established platform for identifying metabolites 
for bio-reprogramming.
FigUre 7 | schematic model for l-valine-induced phagocytosis in 
macrophages.
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l-valine, an essential amino acid, has more functions than just 
in nutrition. In a previous study, mice fed with synthetic diets 
with limited l-valine exhibited obviously increased susceptibility 
to bacterial infection (40), indicating the anti-infective potential 
of l-valine; valine supplementation is not currently used in the 
clinic. However, the mechanism underlying this anti-infection 
property is unknown. A recent paper revealed the immunologi-
cal function of l-valine in DCs and demonstrated that l-valine 
deficiency inhibits the differentiation of monocytes into mature 
DCs as well as IL-12 production, likely by downregulating the 
mTORC1/S6K signaling pathway, which may be the cause of 
enhanced sensitivity to bacterial infection in cirrhotic patients 
(16). Normally, PI3K/Akt is the upstream activator of mTORC1 
(33, 41). Our study found that l-valine is capable of boosting 
PI3K/Akt1 activation in macrophages. PI3K inhibition partially 
reduced the l-valine-induced phagocytosis of bacteria, which is 
consistent with previous studies showing that PI3K/Akt activa-
tion mediates macrophage phagocytosis (42, 43).
We also addressed whether the mechanism of l-valine-
enhanced phagocytosis of bacteria in macrophage is associated 
with NO production. Although phagocytosis and NO production 
are believed to clear pathogens, their intercorrelation has not been 
actually established. Our study revealed that l-valine induced 
macrophages to engulf bacteria through NO and that NO played 
a major role in the direct intracellular-mediated mechanism that 
leads to killing pathogens (44). Meanwhile, NO produced by iNOS 
functions as a signaling molecule, which could strengthen the 
phagocytosis by LPS-stimulated or IFN-γ-primed macrophages 
(45, 46). Furthermore, engagement of Fcγ-receptors triggered 
neuronal and endothelial NOS activity (nNOS and eNOS), both 
of which produced low levels of NO that functioned to promote 
macrophage phagocytosis (47). The present study showed that 
iNOS and eNOS were the two major metabolic enzymes that 
produce NO in l-valine-treated macrophages. Inhibitors of iNOS 
and eNOS reduced l-valine-enhanced phagocytosis. In fact, pro-
moting NO production with l-valine has been documented in 
the literature (34, 35). However, the ability of l-valine to enhance 
NO production and in turn increase bacterial phagocytosis by 
macrophages was previously unrecognized. However, it is help-
ful if primary murine macrophages, NOS KO macrophages, 
and human macrophages can be used to further confirm our 
conclusions.
Another finding in this study is that l-arginine was essen-
tial for l-valine-enhanced phagocytosis and NO production. 
l-arginine is the sole metabolic source for NO production. 
Factors that limited the availability of l-arginine could reduce 
the production of NO, thereby increasing host susceptibility to 
invading pathogens (48). In mammalian cells, arginase and NOS 
compete with one another for l-arginine as an enzyme substrate. 
Deprivation of l-arginine leads to the reduced translational 
efficiency of iNOS mRNA and stability of iNOS protein (49, 50). 
Although the enzymatic activities of arginase and NOS are co-
induced in macrophages in response to bacterial infection, the 
role of arginase is obviously stronger than that of NOS (51, 52), 
indicating that arginase is the predominant regulator of arginine 
availability in activated macrophages. Furthermore, inhibition of 
arginase activity in macrophages increases host survival during 
Toxoplasma gondii infection and reduces the bacterial burden 
in the lung during tuberculosis infection (52). These data are 
consistent with our finding that arginase increases the survival 
of clinically relevant multidrug-resistant isolates. Addition 
of l-arginine reinforces that phagocytosis in l-valine-treated 
macrophages and valine–arginine combination therapy further 
reduces the bacterial load in tissues, proving the significance of 
l-arginine availability in eliminating the bacterial infection.
Although the findings on exogenous metabolite-induced cel-
lular l-valine/arginine elevation and l-valine-enhanced phago-
cytosis in  vitro correlate with elevated host l-valine/arginine 
and bacterial control in  vivo, further investigation is required 
to determine whether the in  vitro mechanism is relevant to 
bacterial control in vivo, which includes examining whether the 
macrophages are really targeted in vivo by l-valine and l-arginine 
administration and determining whether other immune cells are 
involved (53). Additionally, two phenotypes of unknown cause 
from the present study will also need to be determined in future 
studies. One is how increasing concentrations of l-valine entail 
weaker effects on urea/NO synthesis (Figures 4B,C). In mammals, 
degradation of l-valine generates propionyl-CoA, which can be 
metabolized to succinyl-CoA by sequential catalytic reactions, 
including propionyl-CoA carboxylase and methylmalonyl-CoA 
racemase. Succinyl-CoA feeds into the Krebs cycle and produces 
NADH, which results in ATP production through mitochondrial 
respiration. During this respiration, reactive oxygen species 
(ROS), a pathway byproduct, are generated due to electron 
transfer to O2 (54). Low concentrations of mitochondrial ROS 
augment macrophage bactericidal activity (55); however, high 
concentrations of mitochondrial ROS may pose a barrier for 
macrophage survival (54, 56). Therefore, we propose that increas-
ing concentrations of l-valine induces overloaded mitochondrial 
ROS, which leads to macrophage dysfunction, thereby weakening 
the activity of NOS and eventually promoting weaker effects on 
urea/NO synthesis. Another phenotype is that phagocytosis is 
inhibited by 20 mM l-arginine supplementation in the absence 
of l-valine (Figure  5B). As mentioned above, the products of 
arginase catalysis are urea and l-ornithine, of which l-ornithine 
may be used for the synthesis of polyamines by macrophages (57). 
High concentrations of polyamines have the ability to inhibit NOS 
activity (58, 59). After l-valine deprivation, excess l-arginine is 
metabolized by arginase to produce abundant polyamines, the 
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latter of which potentially suppress the activity of eNOS, a con-
stitutively expressed enzyme in RAW264.7 cells (36). This process 
thereby reduces eNOS-mediated NO production and eventually 
decreases NO-mediated phagocytosis by macrophages.
In summary, we demonstrated that mouse resistance to bacte-
rial infection is strongly associated with metabolic states. High 
levels of l-valine are vital for survival strategies by pathogen-
infected hosts. Although how the host accumulates high levels of 
l-valine in vivo upon bacterial infection is unknown, our study 
provides a new clue to identifying metabolic modulators and 
highlights the possibility of employing this metabolic modulator-
mediated innate immunity as a therapy for bacterial infections.
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